Quantity changes in acute headache medication use among patients with chronic migraine treated with eptinezumab: subanalysis of the PROMISE-2 study

Quantity changes in acute headache medication use among patients with chronic migraine treated with eptinezumab: subanalysis of the PROMISE-2 study

Abstract Background Patients with chronic migraine (CM) treated with eptinezumab in the PROMISE-2 trial achieved greater reductions in migraine and headache frequency, impact, and acute headache medication (AHM) use than did patients who received placebo. This post hoc analysis examines relationship...

Full description

Bibliographic Details
Main Authors:	Robert P. Cowan, Michael J. Marmura, Hans-Christoph Diener, Amaal J. Starling, Jack Schim, Joe Hirman, Thomas Brevig, Roger Cady
Format:	Article
Language:	English
Published:	BMC 2022-09-01
Series:	The Journal of Headache and Pain
Subjects:	Chronic migraine Eptinezumab Medication-overuse headache Serotonin 5-HT1 receptor agonists Analgesics
Online Access:	https://doi.org/10.1186/s10194-022-01482-0

Similar Items

Managing Migraine: Medication Overuse Headache and Treatment with Eptinezumab
by: Nicole Limberg
Published: (2023-06-01)

Efficacy and safety of eptinezumab in patients with chronic migraine and medication-overuse headache: a randomized, double-blind, placebo-controlled study
by: Shengyuan Yu, et al.
Published: (2023-12-01)

Adding eptinezumab to brief patient education to treat chronic migraine and medication-overuse headache: Protocol for RESOLUTION—A phase 4, multinational, randomized, double-blind, placebo-controlled study
by: Rigmor H. Jensen, et al.
Published: (2023-02-01)

Shift in diagnostic classification of migraine after initiation of preventive treatment with eptinezumab: post hoc analysis of the PROMISE studies
by: Patricia Pozo-Rosich, et al.
Published: (2022-10-01)

Early clinical experience with eptinezumab: results of a retrospective observational study of patient response in the United States
by: Amaal J. Starling, et al.
Published: (2023-04-01)

Cardiovascular outcomes in adults with migraine treated with eptinezumab for migraine prevention: pooled data from four randomized, double-blind, placebo-controlled studies
by: Timothy R. Smith, et al.
Published: (2021-11-01)

Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials
by: Timothy R. Smith, et al.
Published: (2021-03-01)

Patient-reported outcomes, health-related quality of life, and acute medication use in patients with a ≥ 75% response to eptinezumab: subgroup pooled analysis of the PROMISE trials
by: Richard B. Lipton, et al.
Published: (2022-02-01)

Long-term reductions in disease impact in patients with chronic migraine following preventive treatment with eptinezumab
by: Andrew Blumenfeld, et al.
Published: (2022-07-01)

Effectiveness and Safety of Eptinezumab in Episodic and Chronic Migraine Headache in the UAE: A Retrospective Study
by: Yazan Bader, et al.
Published: (2023-07-01)

Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trial
by: David Kudrow, et al.
Published: (2021-03-01)

Measuring dose-related efficacy of eptinezumab for migraine prevention: post hoc analysis of PROMISE-1 and PROMISE-2
by: Rami Apelian, et al.
Published: (2022-04-01)

Efficacy and safety of eptinezumab for migraine: A systematic review and meta-analysis
by: Yi Zhong, et al.
Published: (2023-01-01)

Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy–2) study
by: Stephen Silberstein, et al.
Published: (2020-10-01)

Rapid resolution of migraine symptoms after initiating the preventive treatment eptinezumab during a migraine attack: results from the randomized RELIEF trial
by: Jessica Ailani, et al.
Published: (2022-06-01)

Tolerability of eptinezumab in overweight, obese or type 1 diabetes patients
by: Brian Baker, et al.
Published: (2021-04-01)

Optimization of acute medication use following eptinezumab initiation during a migraine attack: post hoc analysis of the RELIEF study
by: Roger Cady, et al.
Published: (2022-07-01)

Eptinezumab for the Prevention of Migraine: Clinical Utility, Patient Preferences and Selection – A Narrative Review
by: Altamura C, et al.
Published: (2023-11-01)

Medication Overuse Headache: How Much Are We Aware?
by: Özlem Ethemoğlu, et al.
Published: (2021-06-01)

Improving to Four or Fewer Monthly Headache Days Per Month Provides a Clinically Meaningful Therapeutic Target for Patients with Chronic Migraine
by: Robert G. Kaniecki, et al.
Published: (2023-06-01)

Eptinezumab treatment initiated during a migraine attack is associated with meaningful improvement in patient-reported outcome measures: secondary results from the randomized controlled RELIEF study
by: Peter McAllister, et al.
Published: (2022-02-01)

Factors Associated with Over-the-Counter Analgesic Overuse among Individuals Experiencing Headache
by: Maram Alshareef
Published: (2022-09-01)

Eptinezumab Demonstrated Efficacy Regardless of Prior Preventive Migraine Treatment Failure Type: Post Hoc Analyses of the DELIVER Study
by: Patricia Pozo-Rosich, et al.
Published: (2024-01-01)

Eptinezumab for the preventive treatment of episodic and chronic migraine: a narrative review
by: Pablo Irimia, et al.
Published: (2024-03-01)

Structural equation modeling for identifying the drivers of health-related quality of life improvement experienced by patients with migraine receiving eptinezumab
by: Linus Jönsson, et al.
Published: (2024-03-01)

Medication Overuse Headaches among Children—The Contribution of Migraine and TTH
by: Jacob Genizi, et al.
Published: (2023-09-01)

Clinical Immunogenicity Evaluation of Eptinezumab, a Therapeutic Humanized Monoclonal Antibody Targeting Calcitonin Gene-Related Peptide (CGRP) for the Preventive Treatment of Migraine
by: Susan Pederson, et al.
Published: (2021-10-01)

Overuse of symptomatic medications among chronic (transformed) migraine patients: profile of drug consumption
by: Abouch Valenty Krymchantowski
Published: (2003-03-01)

The journey from genetic predisposition to medication overuse headache to its acquisition as sequela of chronic migraine
by: Paolo Martelletti
Published: (2018-01-01)

A Descriptive Review of Medication-Overuse Headache: From Pathophysiology to the Comorbidities
by: Srdjan Ljubisavljevic, et al.
Published: (2023-10-01)

Management of medication overuse (MO) and medication overuse headache (MOH) S1 guideline
by: Hans-Christoph Diener, et al.
Published: (2022-08-01)

Population pharmacokinetic and exposure‐response analysis of eptinezumab in the treatment of episodic and chronic migraine
by: Brian Baker, et al.
Published: (2020-04-01)

An economic evaluation of eptinezumab for the preventive treatment of migraine in the UK, with consideration for natural history and work productivity
by: Edward Griffin, et al.
Published: (2024-04-01)

Role of Endo-opioid and Endo-cannabinoid Systems in Migraine and Medication-overuse Headache
by: Gökçen Hatipoğlu, et al.
Published: (2022-12-01)

Association between suicidal risks and medication-overuse headache in chronic migraine: a cross-sectional study
by: Yen-Feng Wang, et al.
Published: (2021-05-01)

Prevention of medication overuse and medication overuse headache in patients with migraine: a randomized, controlled, parallel, allocation-blinded, multicenter, prospective trial using a mobile software application
by: Hans-Christoph Diener, et al.
Published: (2022-05-01)

Galcanezumab for the treatment of chronic migraine and medication overuse headache: Real‐world clinical evidence in a severely impaired patient population
by: Simona Guerzoni, et al.
Published: (2023-06-01)

Medication-overuse headache. Retrospective comparison of preventive treatments
by: Abouch V. Krymchantowski, et al.

Headaches in general medical practice
by: Gyuzyal R. Tabeeva
Published: (2022-01-01)

Internal stigmatization in patients with chronic migraine and medication overuse headache
by: Firdevs Ezgi Uçan Tokuç, et al.
Published: (2024-03-01)